NCT00002357 is a Phase 2 clinical trial of HBY 097 in HIV Infections, sponsored by Hoechst Marion Roussel.

Who is sponsoring NCT00002357?

NCT00002357 is sponsored by Hoechst Marion Roussel.

What drugs are being tested in NCT00002357?

Interventions in NCT00002357: HBY 097, Zidovudine.

What condition does NCT00002357 study?

NCT00002357 studies HIV Infections.

Is NCT00002357 still recruiting?

NCT00002357 is currently completed. Last updated 23 June 2005.

Last reviewed 2005-06-23 · How we verify

NCT00002357

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Randomized, Double-Blinded, Dose-Escalation Study Evaluating the Safety and Antiretroviral Activity of HBY 097 Versus HBY 097 Plus AZT in Patients With Asymptomatic or Mildly Symptomatic HIV Infection

Completed Phase 2 Last updated 23 June 2005

What this trial tests

Phase 2 trial testing HBY 097 in HIV Infections in 144 participants. Completed.

Quick facts

Lead sponsor	Hoechst Marion Roussel
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Masking	double
Primary purpose	treatment
Enrollment	144
Sites	6 locations across United States

Drugs / interventions tested

HBY 097 — full drug profile →
Zidovudine (ZIDOVUDINE) — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Hoechst Marion Roussel — full company profile →

Who can join

13 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone. PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00002357 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoechst Marion Roussel
Last refreshed: 23 June 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00002357.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing